Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer.

Hung, Jo-Ni; Hsu, Shih-Tien; Sun, Lou; Hwang, Sheau-Feng; Liu, Chih-Ku; Shih, Yu-Hsiang; Chen, Ming-Jer; Wang, Jun-Sing; Lu, Chien-Hsing

Hung, Jo-Ni; Hsu, Shih-Tien; Sun, Lou; Hwang, Sheau-Feng; Liu, Chih-Ku; Shih, Yu-Hsiang; Chen, Ming-Jer; Wang, Jun-Sing; Lu, Chien-Hsing.

Afiliação

Hung JN; Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.
Hsu ST; Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.
Sun L; Center for General Education, Ling Tung University, Taichung, Taiwan.
Hwang SF; School of Medicine, China Medical University, Taichung, Taiwan.
Liu CK; Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.
Shih YH; Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.
Chen MJ; Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.
Wang JS; Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.
Lu CH; Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.

Front Oncol ; 12: 843278, 2022.

Article em En | MEDLINE | ID: mdl-35664738

Palavras-chave

bevacizumab (Avastin®); progression; real-world study; recurrent epithelial ovarian cancer; survival outcome

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google